Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.92 |
| ▸ | PGR | P06401 | 3/20 | 0.92 |
| ▸ | TSHR | P16473 | 2/20 | 0.92 |
| ▸ | AR | P10275 | 2/20 | 0.92 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.92 |
| ▸ | MEN1 | O00255 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.92 |
| ▸ | APEX1 | P27695 | 1/20 | 0.92 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.92 |
| ▸ | IKBKB | O14920 | 1/20 | 0.92 |
| ▸ | CHUK | O15111 | 1/20 | 0.92 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.92 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.92 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.92 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL2808007 | 1.00 | HIF1A (0.92) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL1301204 | 1.00 | HIF1A (0.92) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL1479323 | 1.00 | HIF1A (0.92) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL29199226 | 0.99 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL29199225 | 0.99 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL5501682 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL8529637 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL73250 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL1561578 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL7426 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115671036-A | Gel medicine for treating fundus and intraocular diseases | 上海交通大学医学院附属第九人民医院 | 2023-02-03 | — | — | CN | disclosed |
| CN-107530339-B | Glucocorticoid receptor antagonists in combination with glucocorticoids for the treatment of adrenal insufficiency | 科赛普特治疗学股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20190201417-A1 | TOPICAL STEROID THERAPY FOR MUCOSAL AND DERMATOLOGICAL INFLAMMATORY DISEASE | CINRX PHARMA, LLC | 2019-07-04 | — | — | US | disclosed |
| WO-2017120125-A1 | TOPICAL STEROID THERAPY FOR MUCOSAL AND DERMATOLOGICAL INFLAMMATORY DISEASES | CINRX PHARMA, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| CN-101742987-B | Process for obtaining steroidal phosphate compounds | HOVIONE INT LTD | 2015-07-22 | — | — | CN | disclosed |
| US-20140249118-A1 | TREATMENT OF ORAL LICHEN PLANUS WITH A COMBINATION OF TRIAMCINOLONE AND RETINOIC ACID | NAJAFI SHAMSOULMOLOUK (IR) | 2014-09-04 | — | — | US | disclosed |
| EP-2148657-B1 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | HOVIONE INT LTD (CH) | 2014-06-04 | — | — | EP | disclosed |
| US-8445471-B2 | Process for obtaining steroidal phosphate compounds | HOVIONE INTER LIMITED (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20100240916-A1 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | HOVIONE INTER LIMITED (CH) | 2010-09-23 | — | — | US | disclosed |
| CN-101742987-A | Be used to obtain the method for steroidal phosphate compounds | HOVIONE INT LTD | 2010-06-16 | — | — | CN | disclosed |
| EP-2148657-A2 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | Hovione Inter Ltd. (CH) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008139210-A2 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | HOVIONE INTER LTD. (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240916-A1 | PROCESS FOR OBTAINING STEROIDAL PHOSPHATE COMPOUNDS | HSD3B1, CYP17A1, HSD3B2 | NR3C1 38/4885HIF1A 2456/4885CYP3A4 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.